Actively Recruiting

Phase 3
Age: 50Years +
All Genders
NCT04570085

Effect of CAFfeine on Cognition in Alzheimer's Disease

Led by University Hospital, Lille · Updated on 2026-04-20

248

Participants Needed

17

Research Sites

352 weeks

Total Duration

On this page

Sponsors

U

University Hospital, Lille

Lead Sponsor

G

Groupement Interrégional de Recherche Clinique et d'Innovation

Collaborating Sponsor

AI-Summary

What this Trial Is About

Sporadic Alzheimer's disease is a multifactorial illness arising a major medico-economic stakes for our aging societies. There is currently no curative treatment available. Coffee is a complex beverage with psychostimulant properties whose main effective element, caffeine, has a pleiotropic effect on the central nervous system. Caffeine pharmacological properties enable its use like an Alzheimer's disease symptomatic treatment. Its supposed benefits mustn't obscure anxiety and insomnia caffeine effect at large dose, which Alzheimer's patients might be more vulnerable. The main study objective is to evaluate placebo-controlled caffeine efficacy (30 treatments weeks) on cognitive decline in Alzheimer's disease dementia at beginning to moderate stage (MMSE 16-24).

CONDITIONS

Official Title

Effect of CAFfeine on Cognition in Alzheimer's Disease

Who Can Participate

Age: 50Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 50 years or older at screening
  • Probable Alzheimer's dementia diagnosed according to National Institute on Aging-Alzheimer's Association criteria, confirmed by brain imaging (CT or MRI) and blood tests including ionogram, kidney and liver function, calcemia, CRP, TSH, B12 vitamins, and folates
  • Mini-Mental State Examination (MMSE) score of 16 or higher
  • Presence of an informant and caregiver living with the patient
  • If using acetylcholinesterase inhibitors and/or memantine, treatment must be stable and effective for at least 2 months before selection and remain stable during the study
Not Eligible

You will not qualify if you...

  • Refusal to follow a low caffeine diet (avoiding tea, caffeinated sodas, and large amounts of chocolate)
  • Current major depressive episode as defined by DSM-5 criteria
  • Other chronic central nervous system disorders
  • Major anxiety diagnosed by clinician with severity >2 and impact >3 on NPI-R scale
  • Sleep disorders with severity and impact on NPI-R; patients with obstructive sleep apnea may participate if device has been used and tolerated for 3 months
  • Decompensated heart disease or severe rhythm disorders (except stable chronic atrial fibrillation)
  • Active smoking
  • Pregnant or planning pregnancy (pregnancy test required for women of childbearing potential)
  • Use of forbidden treatments including psychotropic drugs introduced or changed less than 2 months before inclusion, chronic use of CYP1A2 inducers or inhibitors, any caffeine-containing products, drugs affecting caffeine metabolism, or drugs interacting with caffeine

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 17 locations

1

CHU Amiens

Amiens, France

Not Yet Recruiting

2

CH Arras

Arras, France

Not Yet Recruiting

3

CH Beauvais

Beauvais, France

Not Yet Recruiting

4

CH Béthune

Béthune, France

Not Yet Recruiting

5

CHU Caen

Caen, France

Not Yet Recruiting

6

CH Calais

Calais, France

Not Yet Recruiting

7

CH Dunkerque

Dunkirk, France

Not Yet Recruiting

8

CH Le Quesnoy

Le Quesnoy, France

Not Yet Recruiting

9

CH Lens

Lens, France

Not Yet Recruiting

10

Hôpital Roger Salengro

Lille, France, 59037

Actively Recruiting

11

CHU Lille consultation mémoire Les Bâteliers

Lille, France

Not Yet Recruiting

12

CH Roubaix

Roubaix, France

Not Yet Recruiting

13

CHU Rouen

Rouen, France

Not Yet Recruiting

14

CH Saint Quentin

Saint-Quentin, France

Not Yet Recruiting

15

CH Seclin

Seclin, France

Not Yet Recruiting

16

CH Tourcoing

Tourcoing, France

Not Yet Recruiting

17

CH Valenciennes

Valenciennes, France

Not Yet Recruiting

Loading map...

Research Team

T

Thibaud LEBOUVIER, MD,PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here